|
"kang y k"的相關文件
顯示項目 46-56 / 56 (共2頁)
1 2 > >>
每頁顯示[10|25|50]項目
| 國立成功大學 |
2020 |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
|
Satoh, T.;Kang, Y.-K.;Chao, Y.;Ryu, M.-H.;Kato, Kato K.;Cheol, Chung H.;Chen, J.-S.;Muro, K.;Ki, Kang W.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Tanimoto, M.;Chen, L.-T.;Boku, N. |
| 臺大學術典藏 |
2019 |
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Yau T.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Kang Y.-K.;Hou M.-M.;Numata K.;Yeo W.;Chopra A.;Ikeda M.;Kuromatsu R.;Moriguchi M.;Chao Y.;Zhao H.;Anderson J.;Cruz C.D.;Kudo M.; Yau T.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M. |
| 國立成功大學 |
2019 |
Safety and efficacy of nivolumab in combination with s-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (a
|
Boku, N.;Ryu, M.-H.;Kato, Kato K.;Chung, H.C.;Minashi, K.;Lee, K.-W.;Cho, H.;Kang, W.K.;Komatsu, Y.;Tsuda, M.;Yamaguchi, K.;Hara, Hara H.;Fumita, S.;Azuma, M.;Chen, L.-T.;Kang, Y.-K. |
| 國立成功大學 |
2019 |
Effect of First-line S-1 Plus Oxaliplatin with or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
|
Yoshikawa, T.;Muro, K.;Shitara, K.;Oh, D.-Y.;Kang, Y.-K.;Chung, H.C.;Kudo, T.;Chin, K.;Kadowaki, S.;Hamamoto, Y.;Hironaka, S.;Yoshida, K.;Yen, C.-J.;Omuro, Y.;Bai, L.-Y.;Maeda, K.;Ozeki, A.;Yoshikawa, R.;Kitagawa, Y. |
| 國立成功大學 |
2019 |
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy re
|
Kato, Kato K.;Satoh, T.;Muro, K.;Yoshikawa, T.;Tamura, Tamura T.;Hamamoto, Y.;Chin, K.;Minashi, K.;Tsuda, M.;Yamaguchi, K.;Machida, N.;Esaki, T.;Goto, M.;Komatsu, Y.;Nakajima, T.E.;Sugimoto, N.;Yoshida, K.;Oki, E.;Nishina, T.;Tsuji, A.;Fujii, H.;Kunieda, Kunieda K.;Saitoh, Saitoh S.;Omuro, Y.;Azuma, M.;Iwamoto, Y.;Taku, K.;Fushida, S.;Chen, L.-T.;Kang, Y.-K.;Boku, N. |
| 國立成功大學 |
2019 |
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Zhu, A.X.;Kang, Y.-K.;Yen, C.-J.;Finn, R.S.;Galle, P.R.;Llovet, J.M.;Assenat, E.;Brandi, G.;Pracht, M.;Lim, H.Y.;Rau, K.-M.;Motomura, K.;Ohno, I.;Merle, P.;Daniele, B.;Shin, D.B.;Gerken, Gerken G.;Borg, C.;Hiriart, J.-B.;Okusaka, T.;Morimoto, Morimoto M.;Hsu, Y.;Abada, P.B.;Kudo, M.;investigators, REACH-2 study |
| 國立成功大學 |
2019 |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim, R.D.;Sarker, D.;Meyer, T.;Yau, T.;Macarulla, T.;Park, J.-W.;Choo, S.P.;Hollebecque, A.;Sung, M.W.;Lim, H.-Y.;Mazzaferro, V.;Trojan, J.;Zhu, A.X.;Yoon, J.-H.;Sharma, Sharma S.;Lin, Z.-Z.;Chan, S.L.;Faivre, S.;Feun, L.G.;Yen, C.-J.;Dufour, J.-F.;Palmer, D.H.;Llovet, J.M.;Manoogian, Manoogian M.;Tugnait, M.;Stransky, N.;Hagel, M.;Kohl, N.E.;Lengauer, C.;Sherwin, C.A.;Schmidt-Kittler, O.;Hoeflich, K.P.;Shi, H.;Wolf, B.B.;Kang, Y.-K. |
| 臺大學術典藏 |
2017 |
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
|
El-Khoueiry A.B.; Sangro B.; Yau T.; Crocenzi T.S.; Kudo M.; CHIUN HSU; Kim T.-Y.; Choo S.-P.; Trojan J.; Welling T.H.; 3rd, Meyer T.; Kang Y.-K.; Yeo W.; Chopra A.; Anderson J.; dela Cruz C.; Lang L.; Neely J.; Tang H.; Dastani H.B.; Melero I. |
| 國立成功大學 |
2014-11 |
Results of a phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary antitumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma
|
Kang, Y. K.; Ryoo, BY; Kim, TY; Lee, KH; Lim, HY; Lee, SJ; Ikeda, M; Okusaka, T; Nadano, S; Lin, CC; Poon, TP; Yen, CJ; McCoon, P; Neumann, F; Vishwantahan, K; DuPont; Lyne, P |
| 國立成功大學 |
2013-06 |
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
|
Roy, A. C.; Park, S. R.; Cunningham, D.; Kang, Y. K.; Chao, Y.; Chen, L. T.; Rees, C.; Lim, H. Y.; Tabernero, J.; Ramos, F. J.; Kujundzic, M.; Cardic, M. B.; Yeh, C. G.; de Gramont, A. |
| 臺大學術典藏 |
2013 |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.; Kang Y.K.; Yang T.-S.; Shun C.-T.; Shao Y.-Y.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; CHIUN HSU; Cheng A.-L. |
顯示項目 46-56 / 56 (共2頁)
1 2 > >>
每頁顯示[10|25|50]項目
|
